VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma

SHANGHAI, June 4, 2023 /PRNewswire/ — This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in subjects with primary open angle glaucoma (POAG) or ocular hypertension (OHT). The primary objective was to evaluate the ocular hypotensive efficacy of 2 concentrations of VVN539 Ophthalmic Solution (0.04% … Read more